Compare HWC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWC | TVTX |
|---|---|---|
| Founded | 1883 | N/A |
| Country | United States | United States |
| Employees | 3658 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | HWC | TVTX |
|---|---|---|
| Price | $75.79 | $57.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $77.67 | $40.62 |
| AVG Volume (30 Days) | 937.0K | ★ 1.3M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.59 | $44.76 |
| Revenue Next Year | $4.42 | $35.51 |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.05 | $15.03 |
| 52 Week High | $79.36 | $60.10 |
| Indicator | HWC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 57.88 |
| Support Level | $73.03 | $53.93 |
| Resistance Level | $79.36 | $59.89 |
| Average True Range (ATR) | 1.41 | 2.58 |
| MACD | -0.29 | -0.40 |
| Stochastic Oscillator | 50.59 | 58.73 |
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.